After treatment, the levels of tumor markers substantially declined (p< 0.05), and Group B had lower expression levels of CA19-9, CA242, and CEA than Group A, with statistically significant differences (p< 0.05) (Table 5). The gene discussed is CEACAM5; the disease is neoplasm.